Thrombomodulin and disseminated intravascular coagulation

Shu Min Lin, Han Pin Kuo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Thrombomodulin (TM) is a thrombin-binding anticoagulant cofactor, which is extensively expressed on the surface of endothelial cells. Human TM is a single-chain type 1 transmembrane glycoprotein containing five extracellular domains. TM is an important endogenous anti-coagulant protein. Thrombin-TM complexes transform the inactive from of protein C into an activated protein C (APC). APC subsequently inactivate the coagulation factors Va and VIIIa, thereby suppressing further thrombin generation. In addition, TM also plays an important role in attenuation of inflammatory responses through inhibition of leukocyte adhesion to endothelial cells, inhibition of complement pathways, neutralization of lipopolysaccharide (LPS) as well as sequestration and degradation of proinflammatory high-mobility group box 1 protein (HMGB1). Thus, the endothelial surface bounded TM prevents dissemination of pro-coagulant and pro-inflammatory molecules and allows these molecules to act locally at the site of injury. In patients with sepsis and disseminated intravascular coagulation (DIC), TM expression is down regulated resulting in dissemination of pro-coagulant and pro-inflammatory molecules throughout the systemic circulation. The dual ability of TM to suppress both coagulation and inflammation makes this molecule a possible drug candidate for the treatment for DIC. A soluble form of recombinant human TM (rhsTM) has been shown to be more effective and safer than heparin in treatment of patients with DIC. In fact, rhsTM has been approved for the treatment of DIC in Japan. This chapter focuses on the critical roles of TM in the cross talk between inflammation and coagulation. Furthermore, this chapter provides a rationale for the clinical application of TM for treatment of DIC.

Original languageEnglish
Title of host publicationDisseminated Intravascular Coagulation (DIC)
Subtitle of host publicationClinical Manifestations, Diagnosis and Treatment Options
PublisherNova Science Publishers, Inc.
Pages41-56
Number of pages16
ISBN (Electronic)9781629483276
ISBN (Print)9781629483238
Publication statusPublished - Jan 1 2013
Externally publishedYes

Fingerprint

Thrombomodulin
Disseminated Intravascular Coagulation
Coagulants
Protein C
Thrombin
Endothelial Cells
Factor VIIIa
Factor Va
HMGB1 Protein
Inflammation
Therapeutics
Anticoagulants
Lipopolysaccharides
Heparin
Sepsis
Glycoproteins
Japan
Leukocytes

Keywords

  • Activated protein C
  • Coagulant factor
  • Disseminated intravascular coagulation
  • Sepsis
  • Thrombin
  • Thrombomodulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, S. M., & Kuo, H. P. (2013). Thrombomodulin and disseminated intravascular coagulation. In Disseminated Intravascular Coagulation (DIC): Clinical Manifestations, Diagnosis and Treatment Options (pp. 41-56). Nova Science Publishers, Inc..

Thrombomodulin and disseminated intravascular coagulation. / Lin, Shu Min; Kuo, Han Pin.

Disseminated Intravascular Coagulation (DIC): Clinical Manifestations, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2013. p. 41-56.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lin, SM & Kuo, HP 2013, Thrombomodulin and disseminated intravascular coagulation. in Disseminated Intravascular Coagulation (DIC): Clinical Manifestations, Diagnosis and Treatment Options. Nova Science Publishers, Inc., pp. 41-56.
Lin SM, Kuo HP. Thrombomodulin and disseminated intravascular coagulation. In Disseminated Intravascular Coagulation (DIC): Clinical Manifestations, Diagnosis and Treatment Options. Nova Science Publishers, Inc. 2013. p. 41-56
Lin, Shu Min ; Kuo, Han Pin. / Thrombomodulin and disseminated intravascular coagulation. Disseminated Intravascular Coagulation (DIC): Clinical Manifestations, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2013. pp. 41-56
@inbook{fbfc6f64820b434790ef5f24f1b6ad2b,
title = "Thrombomodulin and disseminated intravascular coagulation",
abstract = "Thrombomodulin (TM) is a thrombin-binding anticoagulant cofactor, which is extensively expressed on the surface of endothelial cells. Human TM is a single-chain type 1 transmembrane glycoprotein containing five extracellular domains. TM is an important endogenous anti-coagulant protein. Thrombin-TM complexes transform the inactive from of protein C into an activated protein C (APC). APC subsequently inactivate the coagulation factors Va and VIIIa, thereby suppressing further thrombin generation. In addition, TM also plays an important role in attenuation of inflammatory responses through inhibition of leukocyte adhesion to endothelial cells, inhibition of complement pathways, neutralization of lipopolysaccharide (LPS) as well as sequestration and degradation of proinflammatory high-mobility group box 1 protein (HMGB1). Thus, the endothelial surface bounded TM prevents dissemination of pro-coagulant and pro-inflammatory molecules and allows these molecules to act locally at the site of injury. In patients with sepsis and disseminated intravascular coagulation (DIC), TM expression is down regulated resulting in dissemination of pro-coagulant and pro-inflammatory molecules throughout the systemic circulation. The dual ability of TM to suppress both coagulation and inflammation makes this molecule a possible drug candidate for the treatment for DIC. A soluble form of recombinant human TM (rhsTM) has been shown to be more effective and safer than heparin in treatment of patients with DIC. In fact, rhsTM has been approved for the treatment of DIC in Japan. This chapter focuses on the critical roles of TM in the cross talk between inflammation and coagulation. Furthermore, this chapter provides a rationale for the clinical application of TM for treatment of DIC.",
keywords = "Activated protein C, Coagulant factor, Disseminated intravascular coagulation, Sepsis, Thrombin, Thrombomodulin",
author = "Lin, {Shu Min} and Kuo, {Han Pin}",
year = "2013",
month = "1",
day = "1",
language = "English",
isbn = "9781629483238",
pages = "41--56",
booktitle = "Disseminated Intravascular Coagulation (DIC)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Thrombomodulin and disseminated intravascular coagulation

AU - Lin, Shu Min

AU - Kuo, Han Pin

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Thrombomodulin (TM) is a thrombin-binding anticoagulant cofactor, which is extensively expressed on the surface of endothelial cells. Human TM is a single-chain type 1 transmembrane glycoprotein containing five extracellular domains. TM is an important endogenous anti-coagulant protein. Thrombin-TM complexes transform the inactive from of protein C into an activated protein C (APC). APC subsequently inactivate the coagulation factors Va and VIIIa, thereby suppressing further thrombin generation. In addition, TM also plays an important role in attenuation of inflammatory responses through inhibition of leukocyte adhesion to endothelial cells, inhibition of complement pathways, neutralization of lipopolysaccharide (LPS) as well as sequestration and degradation of proinflammatory high-mobility group box 1 protein (HMGB1). Thus, the endothelial surface bounded TM prevents dissemination of pro-coagulant and pro-inflammatory molecules and allows these molecules to act locally at the site of injury. In patients with sepsis and disseminated intravascular coagulation (DIC), TM expression is down regulated resulting in dissemination of pro-coagulant and pro-inflammatory molecules throughout the systemic circulation. The dual ability of TM to suppress both coagulation and inflammation makes this molecule a possible drug candidate for the treatment for DIC. A soluble form of recombinant human TM (rhsTM) has been shown to be more effective and safer than heparin in treatment of patients with DIC. In fact, rhsTM has been approved for the treatment of DIC in Japan. This chapter focuses on the critical roles of TM in the cross talk between inflammation and coagulation. Furthermore, this chapter provides a rationale for the clinical application of TM for treatment of DIC.

AB - Thrombomodulin (TM) is a thrombin-binding anticoagulant cofactor, which is extensively expressed on the surface of endothelial cells. Human TM is a single-chain type 1 transmembrane glycoprotein containing five extracellular domains. TM is an important endogenous anti-coagulant protein. Thrombin-TM complexes transform the inactive from of protein C into an activated protein C (APC). APC subsequently inactivate the coagulation factors Va and VIIIa, thereby suppressing further thrombin generation. In addition, TM also plays an important role in attenuation of inflammatory responses through inhibition of leukocyte adhesion to endothelial cells, inhibition of complement pathways, neutralization of lipopolysaccharide (LPS) as well as sequestration and degradation of proinflammatory high-mobility group box 1 protein (HMGB1). Thus, the endothelial surface bounded TM prevents dissemination of pro-coagulant and pro-inflammatory molecules and allows these molecules to act locally at the site of injury. In patients with sepsis and disseminated intravascular coagulation (DIC), TM expression is down regulated resulting in dissemination of pro-coagulant and pro-inflammatory molecules throughout the systemic circulation. The dual ability of TM to suppress both coagulation and inflammation makes this molecule a possible drug candidate for the treatment for DIC. A soluble form of recombinant human TM (rhsTM) has been shown to be more effective and safer than heparin in treatment of patients with DIC. In fact, rhsTM has been approved for the treatment of DIC in Japan. This chapter focuses on the critical roles of TM in the cross talk between inflammation and coagulation. Furthermore, this chapter provides a rationale for the clinical application of TM for treatment of DIC.

KW - Activated protein C

KW - Coagulant factor

KW - Disseminated intravascular coagulation

KW - Sepsis

KW - Thrombin

KW - Thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=84953211370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953211370&partnerID=8YFLogxK

M3 - Chapter

SN - 9781629483238

SP - 41

EP - 56

BT - Disseminated Intravascular Coagulation (DIC)

PB - Nova Science Publishers, Inc.

ER -